Carlos Riveros is a specialist in Internal Medicine, Born in Barranquilla, raised in Cartagena, who is currently based in the United States.
His impotence when he saw friends and patients die from Covid-19 led him to evaluate and study the material that has been working on the virus and on the former SARS (Severe Acute Respiratory Syndrome).
Your concern led him to create a treatment against the virus which apparently can slow down replication of this.
“The fear and the need to build something arose in me because I was just sitting idle at that moment, hoping that by grace and deed the patients would improve and be saved.”
For Riveros, as a clinician, specialized twice in Internal Medicine in Colombia and abroad, the priority, rather than finding a cure or a vaccine, was to find a way to neutralize the coronavirus in the first stage of the disease, in order to avoid patients having to enter an intensive care unit, that is why his research focused on looking for ‘something’ that could be used in primary care.
The doctor qualifies as a success have focused on the primary phase of the virus because that was what led him to determine the correct fusion between two drugs that have so far proven effective against infection.
“I deviated a bit from the common situation, what should we do in an ICU when the patient is already very complicated. And I said: we need more research in the most primary part, anticipating the time of the complication and that’s where I focused and thank God I managed to reach a conclusion that something that inhibits viral replication could work and that in turn decreases airway inflammation. I was surprised that it could not only be effective against coronavirus, but also against other viruses. “
The treatment, which has inhalations or nebulisations as a mode of use, was initially used by the doctor under a situation of occupational risk in which he thought he had been infected, although he did not present symptoms, and it was then used by a close colleague who did develop mild pneumonia, which improved after the third dose. Which led to the drug being spread among close family and friends.
The study, which has been ongoing for between four and six months, is located in Invima, passed the first safety phase and is currently in the second efficacy phase.